Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

Attenuated plasmodium sporozoite expressing MAGE-A3 induces antigen-specific CD8+ T cell response against lung cancer in mice

Zhou, D., Zheng, H., Quanxing, L., Lu, X., Deng, X., Li, J., Bing, H., Fu, Y., Zhu, F., Ding, Y. P., et al. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0309 · Cited by 24

A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)

Watanabe, S., Furuya, N., Nakamura, A., Shiihara, J., Nakachi, I., Tanaka, H., Nakao, M., Minato, K., Seike, M., Sasaki, S., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113469 · Cited by 26

Gene expression of MAGE‐A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non–small cell lung cancer patients

Pan, S., Su, K., Spiessens, B., Kusuma, N., Delahaye, N. F., Gruselle, O., Myo, A., Creus, A. D., Louahed, J., Chang, G.-C., et al. (2016) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12586 · Cited by 24

ASP 8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer

Azuma, K., Nishio, M., Hayashi, H., Kiura, K., Satouchi, M., Sugawara, S., Hida, T., Iwamoto, Y., Inoue, A., Takeda, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13651 · Cited by 23

Impact of tumor sequencing on the use of anticancer drugs

Thomas, F., Desmedt, C., Aftimos, P. G., & Awada, A. H. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000078 · Cited by 23

Management of Egfr-Mutated Non-Small-Cell Lung Cancer: Practical Implications from a Clinical and Pathology Perspective

Cabanero, M., Sangha, R. S., Sheffield, B. S., Sukhai, M. A., Pakkal, M., Kamel‐Reid, S., Karsan, A., Ionescu, D. N., Juergens, R. A., Butts, C. A., et al. (2017) · Current Oncology · doi:10.3747/co.24.3524 · Cited by 24

Effect of double mutations T790M/L858R on conformation and drug-resistant mechanism of epidermal growth factor receptor explored by molecular dynamics simulations

Yan, F., Liu, X., Zhang, S., Su, J., Zhang, Q., & Chen, J. (2018) · RSC Advances · doi:10.1039/c8ra06844e · Cited by 23

LncRNA BC promotes lung adenocarcinoma progression by modulating IMPAD1 alternative splicing

Chen, Q. W., Cai, Q., Yang, Y., Dong, S., Liu, Y. Y., Chen, Z. Y., Kang, C. L., Qi, B., Dong, Y. W., Wu, W., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1129 · Cited by 22

EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non–small cell lung cancer

Yang, C., Ma, S., Zhang, J., Han, Y., Wan, L., Zhou, W., Dong, X., Yang, W., Chen, Y., Gao, L., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2317790121 · Cited by 23

Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC

Somasundaram, A., Socinski, M. A., & Burns, T. F. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.971013 · Cited by 23

Epidermal growth factor receptor endocytic traffic perturbation by phosphatidate phosphohydrolase inhibition: new strategy against cancer

Shaughnessy, R., Retamal, C., Oyanadel, C., Norambuena, A., López, A., Bravo‐Zehnder, M., Montecino, F., Metz, C., Soza, A., & González, A. (2014) · FEBS Journal · doi:10.1111/febs.12770 · Cited by 23

Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance

Zhao, Z.-R., Wang, J., Lin, Y., Wang, F., Fu, S., Zhang, S.-L., Su, X., Jiang, L., Zhang, Y.-G., Shao, J., et al. (2013) · Medical Oncology · doi:10.1007/s12032-013-0810-6 · Cited by 23

A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403

Oda, N., Hotta, K., Ninomiya, K., Minami, D., Ichihara, E., Murakami, T., Yokoyama, T., Ichikawa, H., Chikamori, K., Takigawa, N., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3694-5 · Cited by 24

Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung Cancer

Cheng, H., & Planken, S. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00311 · Cited by 23

MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastoma

Yazdi, M. P., Barjasteh, A., & Moghbeli, M. (2024) · Molecular Brain · doi:10.1186/s13041-024-01113-6 · Cited by 25

Integrin α5 promotes migration and invasion through the FAK/STAT3/AKT signaling pathway in icotinib‑resistant non‑small cell lung cancer cells

Yang, Y., Wang, Y., Che, X., Hou, K., Wu, J., Zheng, C., Yang, C. H., Liu, Y., Hu, X., & Zhang, J. (2021) · Oncology Letters · doi:10.3892/ol.2021.12817 · Cited by 22

Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma

Chua, K. N., Kong, L. R., Sim, W. J., Ng, H. C., Ong, W. R., Thiery, J. P., Huynh, H. T., & Goh, B. C. (2015) · Oncotarget · doi:10.18632/oncotarget.5031 · Cited by 22

Small Molecule T315 Promotes Casitas B-Lineage Lymphoma–Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation

Huang, K., Kao, S.-H., Wang, W.-L., Chen, C., Hsiao, T.-H., Salunke, S. B., Chen, J. J. W., Su, K., Yang, S., Hong, T.-M., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201502-0250oc · Cited by 23

Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors

Wurz, R. P., Pettus, L. H., Ashton, K., Brown, J., Chen, J. J., Herberich, B., Hong, F., Harrington, E. H., Nguyen, T. T., Jean, D. J. S., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00193 · Cited by 22

NF-κB activation is an early event of changes in gene regulation for acquiring drug resistance in human adenocarcinoma PC-9 cells

Fukuoka, M., Yoshioka, K., & Hohjoh, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201796 · Cited by 22

Exploring 4th generation EGFR inhibitors: A review of clinical outcomes and structural binding insights

Tariq, A., Shoaib, M., Qu, L., Shoukat, S., Nan, X., & Song, J. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177608 · Cited by 22

Expression of Na+–K+-2Cl−cotransporter isoform 1 (NKCC1) predicts poor prognosis in lung adenocarcinoma andEGFR-mutated adenocarcinoma patients

Sun, P.-L., Jin, Y., Park, S. Y., Kim, H., Park, E., Jheon, S., Kim, K., Lee, C.-T., & Chung, J.-H. (2015) · QJM · doi:10.1093/qjmed/hcv207 · Cited by 21

EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer

Selenz, C., Compes, A., Nill, M., Borchmann, S., Odenthal, M., Florin, A., Brägelmann, J., Büttner, R., Meder, L., & Ullrich, R. T. (2022) · Cancers · doi:10.3390/cancers14163943 · Cited by 21

Oncogenic growth factor signaling mediating tumor escape from cellular immunity

Concha-Benavente, F., & Ferris, R. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.004 · Cited by 20

Tyrosine kinase-independent actions of DDR2 in tumor cells and cancer-associated fibroblasts influence tumor invasion, migration and metastasis

Barcus, C. E., Hwang, P. Y., Morikis, V. A., Brenot, A., Pence, P., Clarke, M., & Longmore, G. D. (2021) · Journal of Cell Science · doi:10.1242/jcs.258431 · Cited by 21

A comparison of QuantStudio™ 3D Digital PCR and ARMS-PCR for measuring plasma EGFR T790M mutations of NSCLC patients

Feng, Q. F., Gai, F., Sang, Y., Zhang, J., Wang, P., Wang, Y., Liu, B., Lin, D., Yu, Y., & Fang, J. (2018) · Cancer Management and Research · doi:10.2147/cmar.s148134 · Cited by 21

Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial

Xiong, A., Ren, S., Liu, H., Miao, L., Wang, L., Chen, J., Li, W., Li, R., Wang, X., Lu, Z., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.06.013 · Cited by 20

Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma

Astore, S., Baciarello, G., Cerbone, L., & Calabrò, F. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.33 · Cited by 20

Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790Min vivo

Kudo, K., Ohashi, K., Makimoto, G., Higo, H., Kato, Y., Kayatani, H., Kurata, Y., Takami, Y., Minami, D., Ninomiya, T., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12063 · Cited by 21

Third-Generation TKI Resistance Due to SCLC Transformation: A Case Report and Brief Review

Shen, C., He, Y., Liu, J., Chen, X., Yu, J., Li, W., Chen, B., Sun, C., & Zhou, C. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s228301 · Cited by 20

Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score

Lee, D.-W., Shin, D., Kim, J. W., Keam, B., Kim, T. M., Kim, H. J., Kim, D., Wu, H.-G., Paek, S. H., Kim, Y. W., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.10.001 · Cited by 20

EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs

Lin, C.-A., Yu, S., Chen, H., Chen, H., Lin, S.-U., Chang, C., Yu, C., Yang, P., & Ho, C. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.021 · Cited by 20

The economic evaluation of personalised oncology medicines: ethical challenges

Lewis, J., Lipworth, W. L., Kerridge, I., & Day, R. O. (2013) · The Medical Journal of Australia · doi:10.5694/mja13.10046 · Cited by 19

HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy

Vathiotis, I. A., Charpidou, A. G., Gavrielatou, N., & Syrigos, K. N. (2021) · Pharmaceuticals · doi:10.3390/ph14121300 · Cited by 20

Development and externally validate MRI-based nomogram to assess EGFR and T790M mutations in patients with metastatic lung adenocarcinoma

Fan, Y., Dong, Y., Wang, H., Wang, H., Sun, X., Wang, X., Zhao, P., Luo, Y., & Jiang, X. (2022) · European Radiology · doi:10.1007/s00330-022-08955-5 · Cited by 19

Design, synthesis and antitumor activity of 5-trifluoromethylpyrimidine derivatives as EGFR inhibitors

Zuo, Y., Li, R., Zhang, Y., Bao, G., Le, Y., & Yan, L. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2128797 · Cited by 19

MLH1V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients withEGFRL858R-positive lung adenocarcinoma

Chiu, C., Ho, H., Doong, H., Yeh, Y., Chen, M., Chou, T., & Tsai, C. (2015) · Oncotarget · doi:10.18632/oncotarget.3511 · Cited by 19

Pre-Clinical Studies of Epigenetic Therapies Targeting Histone Modifiers in Lung Cancer

Huffman, K. E., & Martínez, E. D. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00235 · Cited by 19

Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer

Lim, J. U., Woo, I. S., Jung, Y. H., Byeon, J. H., Park, C. K., Kim, T. J., & Kim, H. R. (2014) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2014.29.6.830 · Cited by 19

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations

Huang, W. F., Liu, A. H., Zhao, H. J., Dong, H., Liu, L. Y., & Cai, S. X. (2015) · Medicine · doi:10.1097/md.0000000000001263 · Cited by 19

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors

Chen, Y., Lai, C., Rau, K., Huang, C.-H., Chang, H., Chao, T.-Y., Tseng, C., Fang, W., Chung, Y., Wang, Y.-H., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2917-6 · Cited by 19

Non–Small Cell Lung Cancer as a Precision Oncology Paradigm: Emerging Targets and Tumor Mutational Burden (TMB)

Tafe, L. J. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000244 · Cited by 19

IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways

Wang, X., Xu, J., Chen, J., Jin, S., Yao, J., Yu, T., Wang, W. T., & Guo, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01167 · Cited by 19

Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non–Small Cell Lung Cancer Detected by 18F-fluorothymidine

Iommelli, F., Rosa, V. D., Terlizzi, C., Monti, M., Panico, M., Fonti, R., & Vecchio, S. D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3657 · Cited by 19

Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung

Reichegger, H., Jochum, W., Förbs, D., Hader, C., & Früh, M. (2016) · Oncology Research and Treatment · doi:10.1159/000446759 · Cited by 18

Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers

Chinsuwan, T., Hirabayashi, K., Mishima, S., Hasegawa, A., Tanaka, M., Mochizuki, H., Shimoi, A., Murakami, T., Yagyu, S., Shimizu, K., et al. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.100728 · Cited by 19

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer

Malik, P. S., Jain, D., & Kumar, L. (2016) · Oncology · doi:10.1159/000447578 · Cited by 17

Inhibiting IGF-1R attenuates cell proliferation and VEGF production in IGF-1R over-expressing EGFR mutant non-small cell lung cancer cells

Yeo, C. D., Kim, Y. A., Lee, H. Y., Kim, J. W., Lee, S. H., Kim, S. J., Kwon, S. S., Kim, Y. H., & Kim, S. C. (2017) · Experimental Lung Research · doi:10.1080/01902148.2017.1282994 · Cited by 18

The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma

Zhu, Y., Wang, W., Zhang, Q., Xu, C., Zhuang, W., Du, K., Chen, G., Lv, T., & Song, Y. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.09.011 · Cited by 18

Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization

Schüler, J. B., Tschuch, C., Klingner, K., Bug, D., Peille, A.-L., de Koning, L., Oswald, E., Klett, H., & Sommergruber, W. (2019) · Cells · doi:10.3390/cells8070740 · Cited by 17

SOX9 promotes epidermal growth factor receptor-tyrosine kinase inhibitor resistance via targeting β-catenin and epithelial to mesenchymal transition in lung cancer

Tripathi, S. K., & Biswal, B. K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119608 · Cited by 18

Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR

Watanabe, M., Kawaguchi, T., Isa, S., Ando, M., Tamiya, A., Kubo, A., Saka, H., Takeo, S., Adachi, H., Tagawa, T., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.06.003 · Cited by 18

Clinical activity of ASP 8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations

Murakami, H., Nokihara, H., Hayashi, H., Seto, T., Park, K., Azuma, K., Tsai, C., Yang, J. C., Nishio, M., Kim, S., et al. (2018) · Cancer Science · doi:10.1111/cas.13724 · Cited by 17

Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer

Jiang, Z., Gu, Z., Yu, X.-M., Cheng, T., & Liu, B. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1447678 · Cited by 22

Usefulness of nanofluidic digital PCR arrays to quantify T790M mutation in EGFR-mutant lung adenocarcinoma.

Isobe, K., Hata, Y., Tochigi, N., Kaburaki, K., Kobayashi, H., Makino, T., Otsuka, H., Ishida, F., Hirota, N., Sano, G., et al. (2015) · PubMed · Cited by 17

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs

Zhang, C., Wei, B., Li, P., Yang, K., Wang, Z., Ma, J., & Guo, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173524 · Cited by 17

Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer

Vyse, S., Howitt, A., & Huang, P. H. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.04.018 · Cited by 16

Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib

Yuan, J., Li, B., Zhang, N., Zhu, H., Zhou, L., Zhang, L., & Yang, M. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.02.007 · Cited by 17

Missense Mutations in Exons 18–24 of EGFR in Hepatocellular Carcinoma Tissues

Panvichian, R., Tantiwetrueangdet, A., Sornmayura, P., & Leelaudomlipi, S. (2015) · BioMed Research International · doi:10.1155/2015/171845 · Cited by 16

Autochthonous murine models for the study of smoker and never-smoker associated lung cancers

Akbay, E. A., & Kim, J. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.06.04 · Cited by 16

Cytoplasmic YAP Expression is Associated with Prolonged Survival in Patients with Lung Adenocarcinomas and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment

Sun, P.-L., Kim, J. E., Yoo, S. B., Kim, H., Jin, Y., Jheon, S., Kim, K., Lee, C. T., & Chung, J. H. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3715-5 · Cited by 16

Afatinib and lung cancer

Jain, P., Khanal, R., Sharma, A., Yan, F., & Sharma, N. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.983083 · Cited by 17

The detectability of the pretreatment EGFR T790M mutations in lung adenocarcinoma using CAST-PCR and digital PCR

Tatematsu, T., Okuda, K., Suzuki, A., Oda, R., Sakane, T., Kawano, O., Haneda, H., Moriyama, S., Sasaki, H., & Nakanishi, R. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.07.02 · Cited by 16

A liquid biopsy in primary lung cancer

Yoneda, K., Imanishi, N., Ichiki, Y., & Tanaka, F. (2018) · Surgery Today · doi:10.1007/s00595-018-1659-2 · Cited by 17

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer

Lee, J., Shim, J., Park, W., Kim, H. K., Sun, J., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.138 · Cited by 15

FBP1 induced by β‐elemene enhances the sensitivity of gefitinib in lung cancer

Li, J., Dai, P., Sun, J., Yu, W., Han, W., & Li, K. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14750 · Cited by 15

Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer

Thomas, M., Fischer, J. R., Andreas, S., Kortsik, C., Grah, C., Serke, M. H., von Eiff, M., Witt, C. C., Kollmeier, J., Müller, E., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00229014 · Cited by 15

Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine

Pool, M., de Boer, H. R., Hooge, M. N. L., van Vugt, M. A. T. M., & de Vries, E. G. E. (2017) · Theranostics · doi:10.7150/thno.17934 · Cited by 15

Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments

Denis, M. G., & Bennouna, J. (2020) · Cancer Management and Research · doi:10.2147/cmar.s218751 · Cited by 16

Upregulated SPAG6 promotes acute myeloid leukemia progression through MYO1D that regulates the EGFR family expression

Mu, J., Yuan, P., Luo, J., Chen, Y., Tian, Y., Ding, L., Zhao, B., Wang, X., Wang, B., & Liu, L. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006920 · Cited by 18

EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand

McKeage, M. J., Elwood, M., Tin, S. T., Khwaounjoo, P., Aye, P. S., Li, A., Sheath, K. L., Shepherd, P., Laking, G. R., Kingston, N. J., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0515-4 · Cited by 16

Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer

Iwama, E., Nakanishi, Y., & Okamoto, I. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1432356 · Cited by 15

Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non–Small Cell Lung Cancer

Liao, D., Yu, L., Shangguan, D., Zhang, Y., Xiao, B., Liu, G., & Yang, N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.905947 · Cited by 14

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

Wu, W.-S., & Chen, Y. (2014) · Journal of Personalized Medicine · doi:10.3390/jpm4030297 · Cited by 14

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report

Brzezniak, C. E., Schmitz, B. A., Peterson, P. G., Degesys, A., Oronsky, B. T., Scicinski, J. J., Caroen, S. Z., & Carter, C. A. (2016) · Case Reports in Oncology · doi:10.1159/000443605 · Cited by 14

Molecular mechanisms of therapy resistance in solid tumors: chasing “moving” targets

Tafe, L. J. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2101-7 · Cited by 14

Oxidized Vitamin C (DHA) Overcomes Resistance to EGFR-targeted Therapy of Lung Cancer through Disturbing Energy Homeostasis

Ye, M., Pang, N., Wan, T., Huang, Y., Wei, T., Jiang, X., Zhou, Y., Huang, Y., Yang, H., Zhang, Z., et al. (2019) · Journal of Cancer · doi:10.7150/jca.28087 · Cited by 14

Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells

Wu, W.-C., Liu, Y., Liao, Y.-H., Hsu, K., Lien, S.-T., Chen, I., Lai, M.-J., Li, Y., Pan, S., Chen, M.-C., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112540 · Cited by 14

Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids

Gong, K., Guo, G., Beckley, N. A., Yang, X., Zhang, Y., Gerber, D. E., Minna, J. D., Burma, S., Zhao, D., Akbay, E. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27276-7 · Cited by 15

Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR‐mutated non–small cell lung cancer

Nonagase, Y., Takeda, M., Azuma, K., Hayashi, H., Haratani, K., Tanaka, K., Yonesaka, K., Ishii, H., Hoshino, T., & Nakagawa, K. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13166 · Cited by 14

Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update

Prabhash, K. (2019) · South Asian Journal of Cancer · doi:10.4103/sajc.sajc_227_18 · Cited by 13

miRNAs and resistance to EGFR—TKIs in EGFR-mutant non-small cell lung cancer: beyond ‘traditional mechanisms’ of resistance

Ricciuti, B. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.569 · Cited by 13

An in Vitro Assay of hERG K+ Channel Potency for a New EGFR Inhibitor FHND004

Jin, T., Hu, B., Chen, S., Wang, Q., Dong, X. Y., Zhang, Y., Zhu, Y., & Zhang, Z. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00577 · Cited by 13

Synthesis and antitumor evaluation of novel 4‐anilino‐7,8‐dihydropyrido[4,3‐d]pyrimidine‐6(5H)‐carboxylate derivatives as potential EGFR inhibitors

Zhang, D., Yan, Y., Jin, G., Liu, B., Ma, X., Han, D., & Jia, X. (2018) · Archiv der Pharmazie · doi:10.1002/ardp.201800110 · Cited by 13

Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations

Kayatani, H., Ohashi, K., Ninomiya, K., Makimoto, G., Nishii, K., Higo, H., Watanabe, H., Kano, H., Kato, Y., Ninomiya, T., et al. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.07.055 · Cited by 15

Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis

Ohashi, K., Ninomiya, K., Yoshioka, H., Bessho, A., Shibayama, T., Aoe, K., Ishikawa, N., Kozuki, T., Kawai, H., Kuyama, S., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.09.024 · Cited by 13

Limb expression 1‐like protein promotes epithelial–mesenchymal transition and epidermal growth factor receptor‐tyrosine kinase inhibitor resistance via nucleolin‐mediated ribosomal RNA synthesis in non‐small cell lung cancer

Li, M., Zhang, J., Meng, X., Liu, B., Xie, S. M., Liu, F., Yao, D., Zhang, J., Shen, H., & Xing, L. (2022) · Cancer Science · doi:10.1111/cas.15687 · Cited by 10

Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives

Costanzo, R., Montanino, A., Maïo, M. D., Piccirillo, M. C., Sandomenico, C., Giordano, P., Daniele, G., Franco, R., Perrone, F., Rocco, G., et al. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.845092 · Cited by 12

Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase Inhibitors: Non-Responders versus Responders

Hsiao, S.-H., Liu, H. E., Lee, H.-L., Lin, C.-L., Chen, W., Wu, Z.-H., Lin, S., Chiang, L.-L., & Chung, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083266 · Cited by 12

EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice

Higo, H., Ohashi, K., Makimoto, G., Nishii, K., Kudo, K., Kayatani, H., Watanabe, H., Kano, H., Ninomiya, K., Hotta, K., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.08.019 · Cited by 15

Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer

Cooke, D. T., Gandara, D. R., Goodwin, N. C., Calhoun, R. F., Lara, P. N., Mack, P. C., & David, E. A. (2014) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2014.03.014 · Cited by 12

A case of resistance to tyrosine kinase inhibitor therapy

Xu, Y., Huang, Z., Gong, L., & Fan, Y. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000540 · Cited by 12

Overcoming Resistance to Targeted Anticancer Drugs

Doroshow, J. H. (2013) · New England Journal of Medicine · doi:10.1056/nejme1311325 · Cited by 12

Neue morphologische und molekulare Aspekte des Lungenkarzinoms

Warth, A., Stenzinger, A., & Weichert, W. (2013) · Der Pathologe · doi:10.1007/s00292-013-1787-9 · Cited by 11

Genomic aberrations associated with erlotinib resistance in non-small cell lung cancer cells.

Serizawa, M., Takahashi, T., Yamamoto, N., & Koh, Y. (2013) · PubMed · Cited by 11

Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients

Kim, L., Saieg, M. A., Maïo, M. D., Gallo, C., Butts, C. A., Ciardiello, F., Feld, R. D., Cheng, D., Gebbia, V., Burgio, M. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15725 · Cited by 11

Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

Claas, A., Atta, L., Gordonov, S., Meyer, A. S., & Lauffenburger, D. A. (2018) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-018-0542-y · Cited by 11

Nanohydroxyapatite-Mediated Imatinib Delivery for Specific Anticancer Applications

Sobierajska, P., Serwotka-Suszczak, A. M., Szymański, D., Marycz, K., & Wiglusz, R. J. (2020) · Molecules · doi:10.3390/molecules25204602 · Cited by 11

Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in EGFR Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial

Li, C., Hsia, T., Yang, S., Chao, K. S. C., Tu, C., Chen, H.-J., & Li, C.-H. (2022) · Integrative Cancer Therapies · doi:10.1177/15347354221086663 · Cited by 12

Epidermal growth factor receptor regulates lineage plasticity driving transformation to small cell lung cancer

Meng, J., He, X., Cai, C. Z., Ma, Q. Z., Li, K., Zhang, B. X., Yin, Y., Shi, M., & Wang, Y. S. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.09.047 · Cited by 10

Impact of EGFR mutations on treatment of non-small cell lung cancer

Johnson, B. E., Jackman, D. M., & Janne, P. A. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0309-3 · Cited by 7

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management

Noronha, V., Rajendra, A., Joshi, A., Patil, V., Menon, N. N., & Prabhash, K. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_51_19 · Cited by 64

New Treatment Strategy for Patients with EGFR -Mutant Lung Cancer

Ninomiya, T., Takigawa, N., Toyooka, S., Hotta, K., Tanimoto, M., & Kiura, K. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.63

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer

Chang, S., Chang, C., & Shih, J. (2011) · Cancers · doi:10.3390/cancers3022667 · Cited by 6

Overcoming Resistance to EGF Receptor Tyrosine Kinase Inhibitors in EGFR -mutated NSCLC

Saad, S., Huang, K., & Halmos, B. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.35 · Cited by 1